載入...
Up-regulation of the Hippo pathway effector TAZ renders lung adenocarcinoma cells harboring EGFR-T790M mutation resistant to gefitinib
BACKGROUND: The T790M mutation of epithelial growth factor receptor (EGFR) is a major cause of the acquired resistance to EGFR tyrosine kinase inhibitor (EGFR-TKIs) treatment for lung cancer patients. The Hippo pathway effector, TAZ, has emerged as a key player in organ growth and tumorigenesis, inc...
Na minha lista:
| 發表在: | Cell Biosci |
|---|---|
| Main Authors: | , , , , , , , |
| 格式: | Artigo |
| 語言: | Inglês |
| 出版: |
BioMed Central
2015
|
| 主題: | |
| 在線閱讀: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4429831/ https://ncbi.nlm.nih.gov/pubmed/25973173 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/2045-3701-5-7 |
| 標簽: |
添加標簽
沒有標簽, 成為第一個標記此記錄!
|